ProtoKinetix Inc. Completes Private Placement

ST. MARYS, W. Va.--(BUSINESS WIRE)--ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that it has completed a non-brokered private placement (the “Offering”) that closed on November 6, 2015. A total of $200,000 was raised with the offering of 5,000,000 units purchased. Each unit is equivalent to one share of common stock of the Company at $0.04 per share and a non-detachable warrant for one share of common stock of the Company exercisable, on or before December 28, 2015, at $0.04 per share.

“I would like to thank our current shareholders for their participation, which allowed for the 100% completion of this Private Placement. The proceeds will be used to meet the Company’s financial obligations through the end of this year.”

The securities offered pursuant to the Offering will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

“I would like to thank our current shareholders for their participation, which allowed for the 100% completion of this Private Placement. The proceeds will be used to meet the Company’s financial obligations through the end of this year.” said Clarence E. Smith, President and Chief Executive Officer.

About ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component. We have commenced testing on autoimmune diseases. These diseases cause the body’s immune system to attack otherwise healthy cells.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release include “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Among these risks are those set forth in a Form 10-K filed on April 14, 2015. It is important that each person reviewing this release understand the significant risks attendant to the operations of ProtoKinetix. ProtoKinetix disclaims any obligation to update any forward-looking statement made herein.